Charles Weijer

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5033779/charles-weijer-publications-by-year.pdf

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

4,568
citations

h-index

61
g-index

5,343
ext. papers

5,343
ext. citations

5
avg, IF

L-index

#	Paper	IF	Citations
186	Ethical considerations within pragmatic randomized controlled trials in dementia: Results from a literature survey <i>Alzheimerh</i> and Dementia: Translational Research and Clinical Interventions, 2022 , 8, e12287	6	1
185	Informed consent in pragmatic trials: results from a survey of trials published 2014-2019. <i>Journal of Medical Ethics</i> , 2021 ,	2.5	4
184	Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies. <i>BMC Medical Ethics</i> , 2021 , 22, 143	2.9	О
183	Experiences of family of individuals in a locked in, minimally conscious state, or vegetative state with the health care system. <i>Brain Injury</i> , 2021 , 35, 8-14	2.1	3
182	Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. <i>Vaccine</i> , 2021 , 39, 633-640	4.1	17
181	Reopening schools safely in the face of COVID-19: Can cluster randomized trials help?. <i>Clinical Trials</i> , 2021 , 18, 371-376	2.2	2
180	Patient Partner Perspectives Regarding Ethically and Clinically Important Aspects of Trial Design in Pragmatic Cluster Randomized Trials for Hemodialysis. <i>Canadian Journal of Kidney Health and Disease</i> , 2021 , 8, 20543581211032818	2.3	
179	Grey Matter - The Problems of Incidental Findings in Neuroimaging Research <i>Journal of Law, Medicine and Ethics</i> , 2021 , 49, 282-284	1.2	1
178	The multiplicity of caregiving burden: a qualitative analysis of families with prolonged disorders of consciousness. <i>Brain Injury</i> , 2021 , 35, 200-208	2.1	6
177	Caregiver reactions to neuroimaging evidence of covert consciousness in patients with severe brain injury: a qualitative interview study. <i>BMC Medical Ethics</i> , 2021 , 22, 105	2.9	1
176	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 257-265	27.4	30
175	Informed consent in cluster randomised trials: a guide for the perplexed. <i>BMJ Open</i> , 2021 , 11, e054213	3	3
174	A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing. <i>Journal of Clinical Epidemiology</i> , 2021 , 137, 45-57	5.7	5
173	Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop. <i>Health Technology Assessment</i> , 2021 , 25, 1-52	4.4	O
172	Ethical Issues in the Design and Conduct of Pragmatic Cluster Randomized Trials in Hemodialysis Care: An Interview Study With Key Stakeholders. <i>Canadian Journal of Kidney Health and Disease</i> , 2020 , 7, 2054358120964119	2.3	2
171	Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster Randomized Trials with Individual-Level Intervention. <i>Ethics & Duman Research</i> , 2020 , 42, 21-28	2.1	4
170	Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials. <i>Clinical Trials</i> , 2020 , 17, 253-263	2.2	14

169	Rules of the Road for Patient-Driven Consent Processes. <i>American Journal of Bioethics</i> , 2020 , 20, 36-37	1.1	2
168	Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). <i>Lancet, The</i> , 2020 , 395, 828-838	40	26
167	It Does Not Matter Whether Research Interventions Are Usual Care. <i>American Journal of Bioethics</i> , 2020 , 20, 47-48	1.1	0
166	Towards the assessment of quality of life in patients with disorders of consciousness. <i>Quality of Life Research</i> , 2020 , 29, 1217-1227	3.7	9
165	Use of multiple period, cluster randomised, crossover trial designs for comparative effectiveness research. <i>BMJ, The</i> , 2020 , 371, m3800	5.9	4
164	Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?. <i>BMJ, The</i> , 2020 , 371, m4258	5.9	6
163	Response. Clinical Trials, 2020 , 17, 461-462	2.2	
162	Ottawa Statement does not impede randomised evaluation of government health programmes. <i>Journal of Medical Ethics</i> , 2020 , 46, 31-33	2.5	4
161	Reporting of key methodological and ethical aspects of cluster trials in hemodialysis require improvement: a systematic review. <i>Trials</i> , 2020 , 21, 752	2.8	4
160	Ethical issues in cluster randomized trials conducted in low- and middle-income countries: an analysis of two case studies. <i>Trials</i> , 2020 , 21, 314	2.8	1
159	Working for the Weekend Is Not Meaningful Work. American Journal of Bioethics, 2019, 19, 48-50	1.1	2
158	A Stepwise Approach to Ethically Assess Pragmatic Cluster Randomized Trials: Implications for Informed Consent for Suicide Prevention Implementation Research. <i>American Journal of Bioethics</i> , 2019 , 19, 101-103	1.1	
157	Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 659-666	7.4	6
156	Ethical issues raised by cluster randomised trials conducted in low-resource settings: identifying gaps in the through an analysis of the PURE Malawi trial. <i>Journal of Medical Ethics</i> , 2019 , 45, 388-393	2.5	1
155	The ethics of psychedelic research in disorders of consciousness. <i>Neuroscience of Consciousness</i> , 2019 , 2019, niz013	3.3	4
154	Informed consent for functional MRI research on comatose patients following severe brain injury: balancing the social benefits of research against patient autonomy. <i>Journal of Medical Ethics</i> , 2019 , 45, 299-303	2.5	3
153	The ethics of cluster randomized trials: response to a proposal for revision of the Ottawa Statement. <i>Journal of Clinical Epidemiology</i> , 2019 , 116, 140-145	5.7	2
152	Ethical issues in the design and conduct of stepped-wedge cluster randomized trials in low-resource settings. <i>Trials</i> , 2019 , 20, 703	2.8	2

151	The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders. <i>Trials</i> , 2019 , 20, 765	2.8	18
150	Stepped-wedge trials should be classified as research for the purpose of ethical review. <i>Clinical Trials</i> , 2019 , 16, 580-588	2.2	4
149	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. <i>Canadian Journal of Kidney Health and Disease</i> , 2019 , 6, 20543	5 8 ₹19	8 9 4394
148	In reply: When and how should we cluster and cross over: methodological and ethical issues (letters 1 and 2). <i>Canadian Journal of Anaesthesia</i> , 2019 , 66, 239-240	3	
147	Research ethics for emerging trial designs: does equipoise need to adapt?. <i>BMJ, The</i> , 2018 , 360, k226	5.9	6
146	TwiC or treat? Are trials within cohorts ethically defensible?. Clinical Trials, 2018, 15, 21-24	2.2	8
145	Ethical implications of excessive cluster sizes in cluster randomised trials. <i>BMJ Quality and Safety</i> , 2018 , 27, 664-670	5.4	4
144	Minimizing the Harm of Accidental Awareness Under General Anesthesia: New Perspectives From Patients Misdiagnosed as Being in a Vegetative State. <i>Anesthesia and Analgesia</i> , 2018 , 126, 1073-1076	3.9	5
143	Accommodating quality and service improvement research within existing ethical principles. <i>Trials</i> , 2018 , 19, 334	2.8	6
142	Thinking clearly about the FIRST trial: addressing ethical challenges in cluster randomised trials of policy interventions involving health providers. <i>Journal of Medical Ethics</i> , 2018 , 44, 593-598	2.5	1
141	Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation. <i>BMC Medical Ethics</i> , 2018 , 19, 14	2.9	27
140	FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial. <i>BMJ Open</i> , 2018 , 8, e022780	3	3
139	An Ethical Analysis of the SUPPORT Trial: Addressing Challenges Posed by a Pragmatic Comparative Effectiveness Randomized Controlled Trial. <i>Kennedy Institute of Ethics Journal</i> , 2018 , 28, 85-118	1.1	8
138	Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol. <i>BMC Medical Ethics</i> , 2018 , 19, 90	2.9	5
137	Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. <i>BMJ, The</i> , 2018 , 363, k1614	5.9	119
136	Engaging knowledge users in development of the CONSORT-Equity 2017 reporting guideline: a qualitative study using in-depth interviews. <i>Research Involvement and Engagement</i> , 2018 , 4, 34	4.4	5
135	Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol. <i>Trials</i> , 2018 , 19, 525	2.8	14
134	Covert narrative capacity: Mental life in patients thought to lack consciousness. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 61-70	5.3	18

(2015-2017)

133	Inadequacy of ethical conduct and reporting of stepped wedge cluster randomized trials: Results from a systematic review. <i>Clinical Trials</i> , 2017 , 14, 333-341	2.2	24
132	How to design efficient cluster randomised trials. <i>BMJ, The</i> , 2017 , 358, j3064	5.9	123
131	Do doctors have a duty to take part in pragmatic randomised trials?. <i>BMJ, The</i> , 2017 , 357, j2817	5.9	7
130	Does Consent Form Follow Function?. American Journal of Bioethics, 2017, 17, 29-31	1.1	1
129	Is the concept of clinical equipoise still relevant to research?. <i>BMJ, The</i> , 2017 , 359, j5787	5.9	20
128	When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework. <i>BMJ Open</i> , 2017 , 7, e015815	3	19
127	The ethics of future trials: qualitative analysis of physiciansQdecision making. <i>Trials</i> , 2016 , 17, 12	2.8	1
126	Ethical considerations in functional magnetic resonance imaging research in acutely comatose patients. <i>Brain</i> , 2016 , 139, 292-9	11.2	22
125	Ethical Criteria for Human Challenge Studies in Infectious Diseases. <i>Public Health Ethics</i> , 2016 , 9, 92-103	3 1.8	61
124	Clinical Equipoise 2016 , 531-541		
124	Clinical Equipoise 2016 , 531-541 Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9	0.9	8
<u>'</u>	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge</i>	0.9	8
123	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9		
123	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9 Cluster-randomized trials: A closer look. <i>Clinical Trials</i> , 2016 , 13, 294-300	2.2	8
123	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9 Cluster-randomized trials: A closer look. <i>Clinical Trials</i> , 2016 , 13, 294-300 What questions can a placebo answer?. <i>Monash Bioethics Review</i> , 2016 , 34, 23-36 An Ethics of Welfare for Patients Diagnosed as Vegetative With Covert Awareness. <i>AJOB</i>	2.2	5
123 122 121	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9 Cluster-randomized trials: A closer look. <i>Clinical Trials</i> , 2016 , 13, 294-300 What questions can a placebo answer?. <i>Monash Bioethics Review</i> , 2016 , 34, 23-36 An Ethics of Welfare for Patients Diagnosed as Vegetative With Covert Awareness. <i>AJOB Neuroscience</i> , 2015 , 6, 31-41	2.2 2.3 0.8	8 5 20
123 122 121 120	Assessing Decision-Making Capacity in Patients with Communication Impairments. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 691-9 Cluster-randomized trials: A closer look. <i>Clinical Trials</i> , 2016 , 13, 294-300 What questions can a placebo answer?. <i>Monash Bioethics Review</i> , 2016 , 34, 23-36 An Ethics of Welfare for Patients Diagnosed as Vegetative With Covert Awareness. <i>AJOB Neuroscience</i> , 2015 , 6, 31-41 A Misunderstanding Concerning Futility. <i>American Journal of Bioethics</i> , 2015 , 15, 59-60	2.2 2.3 0.8	8 5 20 6

115	The Ottawa statement on the ethical design and conduct of cluster randomized trials: A short report. <i>Research Ethics</i> , 2015 , 11, 52-60	2.8	
114	Acknowledging awareness: informing families of individual research results for patients in the vegetative state. <i>Journal of Medical Ethics</i> , 2015 , 41, 534-8	2.5	17
113	A Scoping Review of Empirical Research Relating to Quality and Effectiveness of Research Ethics Review. <i>PLoS ONE</i> , 2015 , 10, e0133639	3.7	48
112	Cluster Randomized Trials, Ethical Implications of 2015 , 897-905		
111	Variability in research ethics review of cluster randomized trials: a scenario-based survey in three countries. <i>Trials</i> , 2014 , 15, 48	2.8	12
110	Resigned professionalism? Non-acute inpatients and resident education. <i>Advances in Health Sciences Education</i> , 2014 , 19, 529-39	3.7	6
109	Ethics of neuroimaging after serious brain injury. BMC Medical Ethics, 2014, 15, 41	2.9	13
108	Why the debate over minimal risk needs to be reconsidered. <i>Journal of Medicine and Philosophy</i> , 2014 , 39, 387-405	1.1	10
107	Position statement on ethics, equipoise and research on charged particle radiation therapy. <i>Journal of Medical Ethics</i> , 2014 , 40, 572-5	2.5	16
106	Toward a science of brain death. American Journal of Bioethics, 2014, 14, 29-31	1.1	8
105	The Ottawa statement on the ethical design and conduct of cluster randomized trials: A short report. <i>Research Ethics</i> , 2014 , 10, 77-85	2.8	
104	Survey of consent practices in cluster randomized trials: improvements are needed in ethical conduct and reporting. <i>Clinical Trials</i> , 2014 , 11, 60-9	2.2	11
103	Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. <i>Trials</i> , 2013 , 14, 159	2.8	15
102	Researchers Querceptions of ethical challenges in cluster randomized trials: a qualitative analysis. <i>Trials</i> , 2013 , 14, 1	2.8	38
101	What do Canadians think about physician-pharmaceutical industry interactions?. <i>Health Policy</i> , 2013 , 112, 255-63	3.2	12
100	Assessing Decision-Making Capacity in the Behaviorally Nonresponsive Patient With Residual Covert Awareness. <i>AJOB Neuroscience</i> , 2013 , 4, 3-14	0.8	39
99	Challenges in the research ethics review of cluster randomized trials: international survey of	2.2	16
	investigators. Clinical Trials, 2013 , 10, 257-68		

97	Ethical issues in cluster-randomized trials in knowledge translation 2013 , 378-391		1
96	Reporting of patient consent in healthcare cluster randomised trials is associated with the type of study interventions and publication characteristics. <i>Journal of Medical Ethics</i> , 2013 , 39, 119-24	2.5	4
95	Assay sensitivity and the epistemic contexts of clinical trials. <i>Perspectives in Biology and Medicine</i> , 2013 , 56, 1-17	1.5	7
94	The Ottawa Statement on the ethical design and conduct of cluster randomised trials: precis for researchers and research ethics committees. <i>BMJ, The</i> , 2013 , 346, f2838	5.9	55
93	The publication of ethically uncertain research: attitudes and practices of journal editors. <i>BMC Medical Ethics</i> , 2012 , 13, 4	2.9	9
92	What is the role and authority of gatekeepers in cluster randomized trials in health research?. <i>Trials</i> , 2012 , 13, 116	2.8	31
91	The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials. <i>PLoS Medicine</i> , 2012 , 9, e1001346	11.6	175
90	Inadequate reporting of research ethics review and informed consent in cluster randomised trials: review of random sample of published trials. <i>BMJ, The</i> , 2011 , 342, d2496	5.9	39
89	Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8. <i>BMJ, The</i> , 2011 , 343, d5886	5.9	102
88	Ethical issues posed by cluster randomized trials in health research. <i>Trials</i> , 2011 , 12, 100	2.8	84
87	Does clinical equipoise apply to cluster randomized trials in health research?. <i>Trials</i> , 2011 , 12, 118	2.8	24
86	Who is the research subject in cluster randomized trials in health research?. <i>Trials</i> , 2011 , 12, 183	2.8	32
85	When is informed consent required in cluster randomized trials in health research?. <i>Trials</i> , 2011 , 12, 202	2.8	62
84	Requirements for ethics committee review for studies submitted to Implementation Science. <i>Implementation Science</i> , 2011 , 6, 32	8.4	11
83	The perspective of an IRB member. American Journal of Bioethics, 2011, 11, 25-7	1.1	2
82	Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery. <i>BMC Medical Ethics</i> , 2010 , 11, 14	2.9	6
81	Commentary: Ethics in conduct of trials in developing countries. <i>BMJ, The</i> , 2010 , 340, c1373	5.9	
80	Providing research results to participants: attitudes and needs of adolescents and parents of children with cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 878-83	2.2	66

79	Decision-making by adolescents and parents of children with cancer regarding health research participation. <i>Pediatrics</i> , 2009 , 124, 959-65	7.4	50
78	A comparison of journal instructions regarding institutional review board approval and conflict-of-interest disclosure between 1995 and 2005. <i>Journal of Medical Ethics</i> , 2009 , 35, 74-8	2.5	40
77	Ethical and policy issues in cluster randomized trials: rationale and design of a mixed methods research study. <i>Trials</i> , 2009 , 10, 61	2.8	33
76	Helsinki discords: FDA, ethics, and international drug trials. <i>Lancet, The</i> , 2009 , 373, 13-4	40	43
75	The Limits of Consent 2009 ,		11
74	Ethical issues associated with the introduction of new surgical devices, or just because we can, doesn@mean we should. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008 , 30, 508-513	1.3	21
73	U.S. Federal Regulations for emergency research: a practical guide and commentary. <i>Academic Emergency Medicine</i> , 2008 , 15, 88-97	3.4	10
72	Revisiting Equipoise: A Response to Gifford. <i>Kennedy Institute of Ethics Journal</i> , 2007 , 17, 227-246	1.1	2
71	The return of research results to participants: pilot questionnaire of adolescents and parents of children with cancer. <i>Pediatric Blood and Cancer</i> , 2007 , 48, 441-6	3	51
70	Evaluating benefits and harms in intensive care research. <i>Intensive Care Medicine</i> , 2007 , 33, 1819-22	14.5	3
69	Ethics of surgical training in developing countries. <i>World Journal of Surgery</i> , 2007 , 31, 2067-9; discussion 2070-1	3.3	29
68	Equipoise and the duty of care in clinical research: a philosophical response to our critics. <i>Journal of Medicine and Philosophy</i> , 2007 , 32, 117-33	1.1	22
67	Refuting the net risks test: a response to Wendler and Miller@ "Assessing research risks systematically". <i>Journal of Medical Ethics</i> , 2007 , 33, 487-90	2.5	13
66	Terri Schiavo: Rest in peace. <i>Cmaj</i> , 2006 , 175, 621-624	3.5	78
65	Obligations in offering to disclose genetic research results. <i>American Journal of Bioethics</i> , 2006 , 6, 44-6; author reply W10-2	1.1	51
64	Trust based obligations of the state and physician-researchers to patient-subjects. <i>Journal of Medical Ethics</i> , 2006 , 32, 542-7	2.5	27
63	Community Consent for Genetic Research 2006,		2
62	Fiduciary obligation in clinical research. <i>Journal of Law, Medicine and Ethics</i> , 2006 , 34, 424-40	1.2	33

(2003-2006)

61	The balm of Gilead: is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?. <i>Journal of Law, Medicine and Ethics</i> , 2006 , 34, 793-8	08.2	11
60	Is clinical research and ethics a zero-sum game?. Critical Care Medicine, 2005, 33, 912-3	1.4	6
59	Risk in emergency research using a waiver of/exception from consent: implications of a structured approach for institutional review board review. <i>Academic Emergency Medicine</i> , 2005 , 12, 1104-12	3.4	7
58	Meaningful work as due inducement. <i>Theoretical Medicine and Bioethics</i> , 2005 , 26, 431-5	0.9	O
57	A critical history of individual and collective ethics in the lineage of Lellouch and Schwartz. <i>Clinical Trials</i> , 2005 , 2, 244-53	2.2	10
56	A death in the family: reflections on the Terri Schiavo case. <i>Cmaj</i> , 2005 , 172, 1197-8	3.5	11
55	Disclosure of research results to research participants: A pilot study of the needs and attitudes of adolescents and parents. <i>Paediatrics and Child Health</i> , 2005 , 10, 332-4	0.7	11
54	Heads or tails: randomized placebo-controlled trials. AMA Journal of Ethics, 2004, 6, 482	1.4	
53	The quest for legitimacy: comment on Cox Macpherson Q Q o strengthen consensus, consult the stakeholders Q Bioethics, 2004, 18, 293-300	2	2
52	When are research risks reasonable in relation to anticipated benefits?. <i>Nature Medicine</i> , 2004 , 10, 570-	3 50.5	154
52 51	When are research risks reasonable in relation to anticipated benefits?. <i>Nature Medicine</i> , 2004 , 10, 570-Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16	3 ₅ 0. ₅	154 34
	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics</i>		
51	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16 Waiver of consent for emergency research. <i>Annals of Emergency Medicine</i> , 2004 , 44, 278-9; author	3.5	34
51 50	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16 Waiver of consent for emergency research. <i>Annals of Emergency Medicine</i> , 2004 , 44, 278-9; author reply 279-80	3.5	34
51 50 49	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16 Waiver of consent for emergency research. <i>Annals of Emergency Medicine</i> , 2004 , 44, 278-9; author reply 279-80 Considerations and costs of disclosing study findings to research participants. <i>Cmaj</i> , 2004 , 170, 1417-9	3.5 2.1 3.5	34 4 64
51 50 49 48	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16 Waiver of consent for emergency research. <i>Annals of Emergency Medicine</i> , 2004 , 44, 278-9; author reply 279-80 Considerations and costs of disclosing study findings to research participants. <i>Cmaj</i> , 2004 , 170, 1417-9 Unethical author attribution. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2003 , 12, 124-30 Offering to return results to research participants: attitudes and needs of principal investigators in	3.5 2.1 3.5 0.9	344643
51 50 49 48 47	Protecting communities in pharmacogenetic and pharmacogenomic research. <i>Pharmacogenomics Journal</i> , 2004 , 4, 9-16 Waiver of consent for emergency research. <i>Annals of Emergency Medicine</i> , 2004 , 44, 278-9; author reply 279-80 Considerations and costs of disclosing study findings to research participants. <i>Cmaj</i> , 2004 , 170, 1417-9 Unethical author attribution. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2003 , 12, 124-30 Offering to return results to research participants: attitudes and needs of principal investigators in the Children@ Oncology Group. <i>Journal of Pediatric Hematology/Oncology</i> , 2003 , 25, 704-8	3.5 2.1 3.5 0.9	 34 4 64 3 46

43	The ethics of placebo-controlled trials. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 1150-3	6.3	8
42	Disclosure of the right of research participants to receive research results: an analysis of consent forms in the Children@ Oncology Group. <i>Cancer</i> , 2003 , 97, 2904-9	6.4	32
41	Informing Study Participants of Research Results: An Ethical Imperative. <i>IRB: Ethics & Human Research</i> , 2003 , 25, 12		190
40	Therapeutic obligation in clinical research. <i>Hastings Center Report</i> , 2003 , 33, 3	3.3	4
39	Informing study participants of research results: an ethical imperative. <i>IRB: Ethics & Human Research</i> , 2003 , 25, 12-9		91
38	I need a placebo like I need a hole in the head. <i>Journal of Law, Medicine and Ethics</i> , 2002 , 30, 69-72	1.2	30
37	The research subject as wage earner. Theoretical Medicine and Bioethics, 2002, 23, 359-76	0.9	16
36	When argument fails. <i>American Journal of Bioethics</i> , 2002 , 2, 10-1	1.1	7
35	The ethics of placebo-controlled trials. New England Journal of Medicine, 2002, 346, 382-3	59.2	9
34	Lessons from everyday lives: a moral justification for acute care research. <i>Critical Care Medicine</i> , 2002 , 30, 1146-51	1.4	48
33	Placebo trials and tribulations. <i>Cmaj</i> , 2002 , 166, 603-4	3.5	7
32	Continuing review of clinical research Canadian-style. Clinical and Investigative Medicine, 2002, 25, 92-3	0.9	
31	A critical appraisal of protections for aboriginal communities in biomedical research. <i>Jurimetrics</i> , 2002 , 42, 187-98		6
30	The research subject as entrepreneur. American Journal of Bioethics, 2001, 1, 67-9	1.1	5
29	Informing patients of uncertainty in clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 2713-4	27.4	2
28	Hospital policy on appropriate use of life-sustaining treatment. University of Toronto Joint Centre for Bioethics/Critical Care Medicine Program Task Force. <i>Critical Care Medicine</i> , 2001 , 29, 187-91	1.4	21
27	Point-counterpoint: should physicians accept gifts from their patients? No: Gifts debase the true value of care. Western Journal of Medicine, 2001, 175, 77		9
26	Benefit-sharing and other protections for communities in genetic research. <i>Clinical Genetics</i> , 2000 , 58, 367-8	4	20

25	The ethical analysis of risk. <i>Journal of Law, Medicine and Ethics</i> , 2000 , 28, 344-61	1.2	119
24	Moral Solutions in Assessing Research Risk. <i>IRB: Ethics & Human Research</i> , 2000 , 22, 6		8
23	For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2000 , 321, 756-8		101
22	Reporting the study populations of clinical trials. Clear transmission or static on the line?. <i>Journal of Clinical Epidemiology</i> , 2000 , 53, 973-9	5.7	35
21	Ethics. Protecting communities in biomedical research. <i>Science</i> , 2000 , 289, 1142-4	33.3	199
20	What@the price of a research subject?. <i>New England Journal of Medicine</i> , 1999 , 341, 1550-1; author reply 1552	59.2	17
19	Selecting subjects for participation in clinical research: one sphere of justice. <i>Journal of Medical Ethics</i> , 1999 , 25, 31-6	2.5	17
18	Protecting communities in research: current guidelines and limits of extrapolation. <i>Nature Genetics</i> , 1999 , 23, 275-80	36.3	131
17	Research involving the vulnerable sick. <i>Accountability in Research</i> , 1999 , 7, 21-36	1.9	10
16	Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?. <i>Schizophrenia Research</i> , 1999 , 35, 211-8; discussion 227-36	3.6	60
15	Thinking Clearly about Research Risk: Implications of the Work of Benjamin Freedman. <i>IRB: Ethics & Human Research</i> , 1999 , 21, 1		22
14	Protecting communities in research: philosophical and pragmatic challenges. <i>Cambridge Quarterly of Healthcare Ethics</i> , 1999 , 8, 501-13	0.9	100
13	Another Tuskegee?. American Journal of Tropical Medicine and Hygiene, 1999, 61, 1-3	3.2	17
12	A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 69-79	5.7	60
11	Monitoring Informed Consent in an Oncology Study Posing Serious Risk to Subjects. <i>IRB: Ethics & Human Research</i> , 1998 , 20, 1		6
10	The IRB@ Role in Assessing the Generalizability of Non-NIH-Funded Clinical Trials. <i>IRB: Ethics & Human Research</i> , 1998 , 20, 1		71
9	Monitoring informed consent in an oncology study posing serious risk to subjects. <i>IRB: Ethics & Human Research</i> , 1998 , 20, 1-6		2
8	Structuring the Review of Human Genetics Protocols Part II: Diagnostic and Screening Studies. <i>IRB:</i> Ethics & Human Research, 1997 , 19, 1		22

7	Placebo Controls Are Not Good Science. <i>IRB: Ethics & Human Research</i> , 1996 , 18, 8		1
6	Placebo orthodoxy in clinical research. I: Empirical and methodological myths. <i>Journal of Law, Medicine and Ethics,</i> 1996 , 24, 243-51	1.2	63
5	Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. <i>Journal of Law, Medicine and Ethics</i> , 1996 , 24, 252-9	1.2	78
4	Evolving ethical issues in selection of subjects for clinical research. <i>Cambridge Quarterly of Healthcare Ethics</i> , 1996 , 5, 334-45	0.9	17
3	In Loco Parentis Minimal Risk as an Ethical Threshold for Research upon Children. <i>Hastings Center Report</i> , 1993 , 23, 13	3.3	71
2	Case notes and charting of bioethical case consultations. <i>HEC Forum</i> , 1993 , 5, 176-95	1.1	5

Evaluating Benefits and Harms in Clinical Research711-717